Drug Trial Radar · NCT03539601
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
Last checked: Nov 20, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
237
Actual
Start
Apr 27, 2018
Primary completion
Dec 11, 2020
Study completion Dec 11, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of age with mild-moderate AD. A Sub-Study of Optical Coherence Tomography and Biomarkers in Subjects ages 2 to \<18 years old, with Mild to Moderate Atopic Dermatitis, treated with Crisaborole Ointment, 2% or Crisaborole Vehicle Ointment or Hydrocortisone Butyrate 0.1% Cream applied BID will also be conducted at select sites.
Conditions
- Atopic Dermatitis
Interventions
Crisaborole ointment, 2%Drug
Applied twice a day (BID)
Hydrocortisone butyrate cream, 0.1%Drug
Applied BID
Pimecrolimus cream, 1%Drug
Applied BID
Crisaborole VehicleDrug
Applied BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in the Eczema Area and Severity Index (EASI) Total Score at Day 29Time frame: Baseline, Day 29
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Discontinuations Due to AEs and SAEsTime frame: From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)
- Number of Participants With Local Tolerability Adverse Events (AEs)Time frame: From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)
- Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Screening up to Day 29
- Number of Participants With Clinically Significant Abnormal Laboratory ParametersTime frame: Screening up to Day 29
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
Dermatology Trial Associates
Bryant, Arkansas
California Dermatology & Clinical Research Institute
Encinitas, California
Park Avenue Dermatology
Orange Park, Florida
Lenus Research & Medical Group, LLC
Sweetwater, Florida
ForCare Clinical Research
Tampa, Florida
DS Research
Louisville, Kentucky
M3-Wake Research, Inc.
Raleigh, North Carolina
Arlington Research Center, Inc.
Arlington, Texas
Tanner Clinic
Layton, Utah
Virginia Clinical Research, Inc
Norfolk, Virginia
ISA - Interdisciplinary Study Association GmbH
Berlin, Germany
Universitaetsklinikum Frankfurt
Frankfurt am Main, Germany
Klinikum der Universitat Munchen
München, Bavaria, Germany
Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz
Bad Bentheim, Lower Saxony, Germany
Universitatsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Universitatsklinikum Schleswig-Holstein, Campus Lubeck
Lübeck, Schleswig-Holstein, Germany
UOSD Dermatologia Gen. ed Oncologica DU, PO San Salvatore
L’Aquila, AQ, Italy
DiSSal Sezione di Dermatologia Az. Ospedaliera Universitaria
Genova, GE, Italy
Ospedale San Pietro Fatebenefratelli
Roma, RM, Italy
Azienda Ospedaliero - Universitaria Policlinico Tor Vergata
Roma, ROME, Italy
Silmedic sp. z o.o
Katowice, Poland
Krakowskie Centrum Medyczne sp. z o.o.
Krakow, Poland
Klinika Ambroziak Sp. z O. O.
Warsaw, Poland
ROYALDERM Agnieszka Nawrocka
Warsaw, Poland
Barbara Rewerska Diamond Clinic
Krakow, Malopolska, Poland
Barn och Ungdomskliniken
Örebro, Sweden
Avdelningen for Kliniska Provningar
Örebro, Sweden
Universitatsklinik fuer Dermatologie
Bern, Switzerland
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
Universitats-Kinderspital Zurich
Zurich, Switzerland
Rame Medical Ltd, Penntorr Health
Torpoint, Cornwall, United Kingdom
NHS Tayside, Ninewells Hospital and Medical School
Dundee, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.